Prashant Kumar: How to Detect, Monitor, and Treat Disease-Ushering in a Personalized Era of Care
Prashant Kumar, Chief Scientific Officer at Datar Cancer Genetics, shared a post on LinkedIn:
“‘Multi-omics and Liquid biopsy: the new frontier in personalized medicine‘ an emerging paradigm that is set to revolutionize how to detect, monitor and treat disease-ushering in a truly personalized era of care. Sharing the recent development in the field to young and curious minds! Their questions, energy, and fresh perspectives are truly inspiring.
I get genuinely excited whenever I have the opportunity to interact with young minds! Overwhelming and enriching experience to dive deep into their curiosity, understanding how they mine information and approach learning.
Knowledge truly grows when shared, and it multiplies when we embark on a mission to both enrich an audience and learn from them in return.
It was a pleasure to visit St. Xavier’s College, Mumbai and engage with some of the most committed faculty members.
Kudos to Dr. Punita Jain, shaping tirelessly with her passion and purpose to the next generation of thinkers!”
More posts featuring Prashant Kumar.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023